Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Commentary|Videos|May 5, 2024
Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy
Author(s)Alexander Kutikov, MD, FACS
Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Advertisement
Alexander Kutikov, MD, FACS, chair and professor, Department of Urology and the Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Advertisement
Related to this article
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
3
TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC
4
Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC
5